GSK Links With OncoMed, Galapagos To Boost Oncologic, Anti-Infective Pipelines
This article was originally published in The Pink Sheet Daily
Executive Summary
Deals present possible $1.4 billion for OncoMed, €245 million for Galapagos through GSK’s external drug discovery centers.